Innovative Cellular Therapeutics Holdings Ltd 4

What Happened
Innovative Cellular Therapeutics Holdings Ltd, listed as a 10% owner of Lyell Immunopharma (LYEL), transferred 38,500 shares of Lyell common stock on July 27, 2026. The shares were reported at $0.00 per share (total reported value $0) and are described as a transfer used to pay a broker commission related to the first Development Milestone under a license agreement dated November 6, 2025. This is a disposition/transfer (transaction code J) rather than a market sale or purchase and does not necessarily indicate a change in sentiment by the holder.

Key Details

• Transaction date: 2026-07-27; reported as Other acquisition/disposition (Code J).
• Price: $0.00 per share; total reported proceeds $0 (transfer as broker commission).
• Shares transferred: 38,500.
• Shares beneficially owned immediately after the transfer: 2,818,980 (2,857,480 prior minus 38,500 transferred).
• Footnote: Transfer to LifeSci Advisors, LLC as broker commission in connection with the first Development Milestone under the Nov. 6, 2025 License Agreement.
• Filing appears timely (reporting date and filing date both 2026-07-27).
• Insider type: 10% owner (institutional/major holder), not an individual executive — different implications than executive insider trades.

Context
This was a stock transfer to cover broker commission tied to a contractual milestone payment, not a cash sale on the open market. Such transfers are often administrative/transactional and do not necessarily reflect the holder’s view of the company’s outlook. For retail investors, outright purchases by insiders can be more informative than routine transfers or commission payments.